Diphtheria-tetanus-acellular pertussis vaccine
Phase 1Vaccine
CanSino Biologics Inc.Diphtheria-tetanus-acellular pertussis vaccine is one of 41 biologic programs targeting Influenza. It is currently in Phase 1.
2
Indications
3
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Crestor
AstraZenecaPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Diphtheria-tetanus-acellular pertussis vaccine
CanSino Biologics Inc.Phase 1
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diphtheria1 trial
Influenza1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 1[1]
- Company